Merck KGaA : Q4 slightly weaker on margins, strong 2022 outlook
>Q4 review – The expected strong sales performance - Group Q4 sales were up 13% y-o-y to € 5.21bn vs our and consensus forecast of € 5.15bn (1% better). A positive surprise was due to the healthcare division, which showed 4.7% y-o-y organic sales growth vs our forecast of only 2%. Life Science showed the expected strong performance in Q4 with 14.2% organic growth (14.5% our estimate) against an already high basis. Electronics showed slightly weaker organic growth than...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.